Xgeva Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The xgeva market research report is one of a series of new reports that provides xgeva market statistics, including xgeva industry global market size, regional shares, competitors with a xgeva market share, detailed xgeva market segments, market trends and opportunities, and any further data you may need to thrive in the xgeva industry. This xgeva market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing incidence of bone-related metastases in cancer patients, growing adoption of Xgeva in cancer treatment regimens, rising awareness of the drug's benefits, and growing aging population. Major trends in the forecast period include expanding indications for bone-related cancers, innovations in treatment delivery methods, and advancements in personalized medicine.

The rising prevalence of bone metastasis is driving the growth of the Xgeva market. Bone metastasis occurs when cancer cells spread from their original site to the bones, often resulting in pain, fractures, and various complications. This increase in bone metastasis is linked to the growing global incidence of cancers, particularly breast, prostate, and lung cancers, which are more likely to spread to the bones. As the number of individuals affected by bone metastasis grows, the need for effective treatments to manage bone-related issues intensifies. Xgeva has become a crucial treatment option for preventing fractures and improving the outcomes for patients with metastatic bone disease. For example, the American Cancer Society reported in January 2024 that the number of bone and joint metastatic cancer cases increased to 3,970 in 2023, up from 3,910 in 2022, marking a 1.5% growth. Therefore, the rising prevalence of bone metastasis is expected to significantly boost the Xgeva market.

A notable trend in the Xgeva market is the development of new formulations aimed at improving patient access and convenience. One such advancement is the introduction of prefilled syringes, which are ready-to-use single-dose syringes preloaded with the medication. These syringes are designed to simplify the administration process, improve dosing accuracy, and enhance patient convenience. For example, in March 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK approved a high-concentration formulation of Xgeva (denosumab), available as a 120 mg solution for injection in a prefilled syringe. This approval, granted under the International Recognition Procedure (IRP), provides UK patients with a more convenient and streamlined treatment option, reducing the volume of liquid injected and minimizing the risk of dosing errors.

In May 2024, Alvotech, a Luxembourg-based company specializing in biosimilar medicines, entered into a collaboration with Dr. Reddy’s Laboratories SA to accelerate the commercialization of AVT03 (denosumab), a biosimilar to Xgeva. This partnership leverages Dr. Reddy’s established presence in the U.S., Europe, and the UK, helping to ensure broader access to affordable treatments for patients with conditions such as osteoporosis and bone-related complications from cancer. Dr. Reddy’s Laboratories SA, an India-based global pharmaceutical company, focuses on developing and manufacturing a wide range of medicines.

The key company operating in the xgeva market is Amgen Inc.

North America was the largest region in the xgeva market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in xgeva report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the xgeva market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Xgeva (denosumab) is a monoclonal antibody used to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors, as well as in the treatment of giant cell tumors of bone and osteoporosis in high-risk patients. It is administered through subcutaneous injections given by a healthcare professional.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary formulations of Xgeva are 60 mg and 120 mg injections. The 60 mg dosage is typically given as a single injection to meet the specific needs of patients, addressing conditions that require lower dosages. Xgeva is indicated for bone metastases, giant cell tumor of bone (GCTB), and hypercalcemia of malignancy. It is used by various end users, including hospitals, homecare settings, specialty clinics, and ambulatory surgical centers. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies.

The xgeva market consists of sales of prefilled syringes and vials. Values in this market are ‘factory gate’ values, representing the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.